ビオフェルミン製薬(株)の貸借残高情報
| 主市場 | 業種 | 証券コード/EDINET | 英名称 |
|---|---|---|---|
| 東証1部 | 医薬品 | 4517/E00960 | BIOFERMIN PHARMACEUTICAL CO.,LTD. |
| 公表日 | 公表 | 貸付残高 | 前週比 | 新規貸付成約高 | 前週比 | 借入残高 | 前週比 | 新規借入成約高 | 前週比 |
|---|---|---|---|---|---|---|---|---|---|
| 2018/12/07 | 日証協 | 8,325株 | +6.73% | 6,990株 | +111.82% | 14,549株 | +4.56% | 1,610株 | +61% |
| 2018/11/30 | 日証協 | 7,800株 | +6.85% | 3,300株 | 0% | 13,914株 | -2.79% | 1,000株 | +50.38% |
| 2018/11/22 | 日証協 | 7,300株 | 0% | 0株 | -100% | 14,314株 | -31.23% | 665株 | -92.93% |
| 2018/11/16 | 日証協 | 7,300株 | -21.4% | 100株 | -96.67% | 20,814株 | +43.41% | 9,400株 | +213.23% |
| 2018/11/09 | 日証協 | 9,288株 | +1.76% | 3,000株 | +13.04% | 14,514株 | -27.84% | 3,001株 | -67.38% |
| 2018/11/02 | 日証協 | 9,127株 | -17.03% | 2,654株 | -33.65% | 20,113株 | +62.54% | 9,200株 | +736.36% |
| 2018/10/26 | 日証協 | 11,000株 | +35.8% | 4,000株 | +238.98% | 12,374株 | +10.35% | 1,100株 | -26.67% |
| 2018/10/19 | 日証協 | 8,100株 | -10.99% | 1,180株 | +1080% | 11,213株 | +0.81% | 1,500株 | +36.36% |
| 2018/10/12 | 日証協 | 9,100株 | -35.92% | 100株 | -99.41% | 11,123株 | -29.7% | 1,100株 | -82.84% |
| 2018/10/05 | 日証協 | 14,200株 | +51.06% | 16,900株 | -22.12% | 15,823株 | +95.08% | 6,410株 | +482.73% |
| 2018/09/28 | 日証協 | 9,400株 | +16.05% | 21,700株 | +294.55% | 8,111株 | -38.17% | 1,100株 | +37.5% |
| 2018/09/21 | 日証協 | 8,100株 | -22.12% | 5,500株 | +5.77% | 13,119株 | -0.72% | 800株 | +60% |
| 2018/09/14 | 日証協 | 10,400株 | +6.12% | 5,200株 | 0% | 13,214株 | +3.93% | 500株 | -73.68% |
| 2018/09/07 | 日証協 | 9,800株 | -9.26% | 5,200株 | -8.77% | 12,714株 | +4.09% | 1,900株 | +46.15% |
| 2018/08/31 | 日証協 | 10,800株 | +4.85% | 5,700株 | +185% | 12,214株 | -3.93% | 1,300株 | +160% |
| 2018/08/24 | 日証協 | 10,300株 | -9.65% | 2,000株 | -44.44% | 12,714株 | -3.78% | 500株 | -72.28% |
| 2018/08/17 | 日証協 | 11,400株 | +7.55% | 3,600株 | -56.63% | 13,214株 | +6.48% | 1,804株 | +20.27% |
| 2018/08/10 | 日証協 | 10,600株 | +19.1% | 8,300株 | +50.91% | 12,410株 | +6.89% | 1,500株 | +87.5% |
| 2018/08/03 | 日証協 | 8,900株 | -5.32% | 5,500株 | -33.73% | 11,610株 | +1.72% | 800株 | 0% |
※株式分割は考慮していませんのでご注意ください。